Vnitr Lek 2006, 52(5):426-428

Respiratory infections and inhalation insulin therapy

Š. Svačina
III. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

A very important change in diabetology will come soon - introduction of inhalation insulin to the market. Experiences with this therapy are now more than 4 years long and no severe complications are present. Respiratory infections are not more frequent and it is not necessary to change insulin dosing during these infections. Insulin is more absorbed in smokers. The research of inhalation insulin brought again attention to diabetic pneumopathy. This disease has no clinical importance as has no relation to inhalation insulin therapy.

Keywords: inhalation insulin; complications of treatment; frequency of infections; diabetic pneumopathy; smoking

Received: August 19, 2005; Accepted: August 19, 2005; Published: May 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Respiratory infections and inhalation insulin therapy. Vnitr Lek. 2006;52(5):426-428.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ardigo D et al. Pulmonary complications in diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy 2004; 3: 3. Go to original source... Go to PubMed...
    2. Heinemann L, Heiser T. Current Status of the Development of Inhaled Insulin. J Diabetes Vasc Dis 2004; 4: 295-301. Go to original source...
    3. Heinemann L et al. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7: 1327-1351. Go to original source... Go to PubMed...
    4. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118: 205-211. Go to original source... Go to PubMed...
    5. McElduff A et al. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AER insulin Diabetes Management System. Br J Clin Pharmacol 2005; 59: 546-551. Go to original source... Go to PubMed...
    6. Odegard PS, Capoccia KL. Inhaled insulin: exubera. Ann Pharmacother 2005; 39: 843-853. Go to original source... Go to PubMed...
    7. Quattrin T et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004; 27: 2622-2627. Go to original source... Go to PubMed...
    8. Svačina Š. Nové trendy v diabetologii. Vnitř Lék 2004; 50(Suppl 1): 76-80. Go to PubMed...
    9. Svačina Š. Léčba inhalačním inzulinem. Farmakoterapie 2005; 1: 18-25.
    10. Svačina Š. Nové formy inzulinoterapie (inhalační, orální, transdermální a tabletový inzulin). In: Trendy v diabetologii. Praha: Galén 2005, vol. 10.
    11. Svačina Š. Prevence diabetu. Praha: Galén 2003.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.